Cancer Research
Overview
Cancer Research is a renowned scientific journal dedicated to advancing our understanding of cancer biology, prevention, diagnosis, and treatment. It publishes cutting-edge research articles, reviews, and perspectives from leading experts worldwide, fostering collaboration and innovation in the fight against cancer.
Details
Details
Abbr.
Cancer Res
Start
1941
End
Continuing
Frequency
Semimonthly <, Jan. 1, 1987->
p-ISSN
0008-5472
e-ISSN
1538-7445
Country
United States
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 31
498
SJR / Ranks: 467
3468
CiteScore / Ranks: 502
16.90
JIF / Ranks: 377
11.2
Recent Articles
11.
Mahuron K, Shahid O, Sao P, Wu C, Haugh A, Huppert L, et al.
Cancer Res
. 2025 Mar;
PMID: 40042995
PD-1 pathway inhibitors have revolutionized cancer therapy. However, most patients do not durably benefit, highlighting the need for biomarkers to stratify patients as responders or non-responders. While CD8+ tumor infiltrating...
12.
Yang X, Deng Y, Ye Y, Meng J, Su M, Wei W, et al.
Cancer Res
. 2025 Mar;
PMID: 40036156
Adaptive resistance to immunotherapy remains a significant challenge in cancer treatment. The reshaping of the tumor immune microenvironment in response to therapeutic pressures is a crucial factor contributing to this...
13.
Wang M, Zou F, Wang S, Yang Y, Xia C, Chen L, et al.
Cancer Res
. 2025 Mar;
PMID: 40036155
As the third most common cause of cancer-related mortality, hepatocellular carcinoma (HCC) is a global health concern. Despite its prevalence, treatment options are limited, underscoring the need to identify potential...
14.
Saleh T, Greenberg E, Faber A, Harada H, Gewirtz D
Cancer Res
. 2025 Mar;
PMID: 40036150
Cancer chemotherapy and radiotherapy are rarely successful in eliminating the entire tumor population, often leaving behind a subpopulation of senescent cells that can contribute to disease recurrence. These senescent tumor...
15.
Teisseire M, Sahu U, Parola J, Tsai M, Vial V, Durivault J, et al.
Cancer Res
. 2025 Mar;
PMID: 40029310
Sunitinib is an oral tyrosine kinase inhibitor used in treating advanced renal cell carcinoma (RCC) that exhibits significant efficacy but faces resistance in 30% of patients. Identifying the molecular mechanisms...
16.
Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T Cell Immunotherapy
Hernandez-Lopez R, Kesti T, Makela A, Zhao Z, Yu W, Tonai Y, et al.
Cancer Res
. 2025 Mar;
PMID: 40029291
Engineered T cell therapies have emerged as a promising approach for cancer treatment, yet their application to solid tumors remains challenging due to the limited specificity and persistence of current...
17.
Sos M, Koker M, Weir B, Heynck S, Rabinovsky R, Zander T, et al.
Cancer Res
. 2025 Mar;
85(5):1003.
PMID: 40025966
No abstract available.
18.
Almeida S, Melo S
Cancer Res
. 2025 Mar;
85(5):833-835.
PMID: 40025965
Senescence, a state of stable cell-cycle arrest, plays a dual role in cancer by suppressing tumor growth while potentially promoting relapse through its secretome, including senescence-associated secretory phenotype factors and...
19.
Seynhaeve A, Liu H, Priester M, Valentijn M, van Holten-Neelen C, Brouwer R, et al.
Cancer Res
. 2025 Feb;
PMID: 40009768
Tumor necrosis factor-alpha (TNFα) induces vascular permeability and plays an important role in inflammation. In addition, TNFα-induced vascular leakage is involved in the increased extravasation of nanoparticle-formulated chemotherapeutic drugs, improving...
20.
Lin Y, Zhang Y, Huang T, Chen J, Li G, Zhang B, et al.
Cancer Res
. 2025 Feb;
PMID: 39992728
Metabolic reprogramming is a hallmark of cancer. Rewiring of amino acid metabolic processes provides the basis for amino acid deprivation therapies. In this study, we found that arginine biosynthesis is...